BioWorld

Aug. 5, 2004

View Archived Issues

Avera's Venture Round Gets $48M For Neuroscience Bid

Although going about the typical process for a biotechnology firm backward, Avera Pharmaceuticals Inc. proved it can make the model work, raising $48 million in a Series C round of venture capital funding. (BioWorld Today) Read More

Ceregene Raises $32M, Sends CNS Therapies Toward Clinic

Read More

Kalypsys Plans To Advance Pipeline With $29M Series B

Read More

Alnylam Acquires Rights To VEGF Patents From Hybridon

Read More

Inex Loses GSK As Partner For Liposomal Cancer Drug

Read More

Other News To Note

Read More